Cargando…

Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma

OBJECTIVES: To identify combined clinical, radiomic, and delta-radiomic features in metastatic gastroesophageal adenocarcinomas (GEAs) that may predict survival outcomes. METHODS: A total of 166 patients with metastatic GEAs on palliative chemotherapy with baseline and treatment/follow-up (8–12 week...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishna, Satheesh, Sertic, Andrew, Liu, Zhihui (Amy), Liu, Zijin, Darling, Gail E., Yeung, Jonathon, Wong, Rebecca, Chen, Eric X., Kalimuthu, Sangeetha, Allen, Michael J., Suzuki, Chihiro, Panov, Elan, Ma, Lucy X., Bach, Yvonne, Jang, Raymond W., Swallow, Carol J., Brar, Savtaj, Elimova, Elena, Veit-Haibach, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461093/
https://www.ncbi.nlm.nih.gov/pubmed/37645426
http://dx.doi.org/10.3389/fonc.2023.892393
_version_ 1785097784978833408
author Krishna, Satheesh
Sertic, Andrew
Liu, Zhihui (Amy)
Liu, Zijin
Darling, Gail E.
Yeung, Jonathon
Wong, Rebecca
Chen, Eric X.
Kalimuthu, Sangeetha
Allen, Michael J.
Suzuki, Chihiro
Panov, Elan
Ma, Lucy X.
Bach, Yvonne
Jang, Raymond W.
Swallow, Carol J.
Brar, Savtaj
Elimova, Elena
Veit-Haibach, Patrick
author_facet Krishna, Satheesh
Sertic, Andrew
Liu, Zhihui (Amy)
Liu, Zijin
Darling, Gail E.
Yeung, Jonathon
Wong, Rebecca
Chen, Eric X.
Kalimuthu, Sangeetha
Allen, Michael J.
Suzuki, Chihiro
Panov, Elan
Ma, Lucy X.
Bach, Yvonne
Jang, Raymond W.
Swallow, Carol J.
Brar, Savtaj
Elimova, Elena
Veit-Haibach, Patrick
author_sort Krishna, Satheesh
collection PubMed
description OBJECTIVES: To identify combined clinical, radiomic, and delta-radiomic features in metastatic gastroesophageal adenocarcinomas (GEAs) that may predict survival outcomes. METHODS: A total of 166 patients with metastatic GEAs on palliative chemotherapy with baseline and treatment/follow-up (8–12 weeks) contrast-enhanced CT were retrospectively identified. Demographic and clinical data were collected. Three-dimensional whole-lesional radiomic analysis was performed on the treatment/follow-up scans. “Delta” radiomic features were calculated based on the change in radiomic parameters compared to the baseline. The univariable analysis (UVA) Cox proportional hazards model was used to select clinical variables predictive of overall survival (OS) and progression-free survival (PFS) (p-value <0.05). The radiomic and “delta” features were then assessed in a multivariable analysis (MVA) Cox model in combination with clinical features identified on UVA. Features with a p-value <0.01 in the MVA models were selected to assess their pairwise correlation. Only non-highly correlated features (Pearson’s correlation coefficient <0.7) were included in the final model. Leave-one-out cross-validation method was used, and the 1-year area under the receiver operating characteristic curve (AUC) was calculated for PFS and OS. RESULTS: Of the 166 patients (median age of 59.8 years), 114 (69%) were male, 139 (84%) were non-Asian, and 147 (89%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. The median PFS and OS on treatment were 3.6 months (95% CI 2.86, 4.63) and 9 months (95% CI 7.49, 11.04), respectively. On UVA, the number of chemotherapy cycles and number of lesions at the end of treatment were associated with both PFS and OS (p < 0.001). ECOG status was associated with OS (p = 0.0063), but not PFS (p = 0.054). Of the delta-radiomic features, delta conventional HUmin, delta gray-level zone length matrix (GLZLM) GLNU, and delta GLZLM LGZE were incorporated into the model for PFS, and delta shape compacity was incorporated in the model for OS. Of the treatment/follow-up radiomic features, shape compacity and neighborhood gray-level dependence matrix (NGLDM) contrast were used in both models. The combined 1-year AUC (Kaplan–Meier estimator) was 0.82 and 0.81 for PFS and OS, respectively. CONCLUSIONS: A combination of clinical, radiomics, and delta-radiomic features may predict PFS and OS in GEAs with reasonable accuracy.
format Online
Article
Text
id pubmed-10461093
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104610932023-08-29 Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma Krishna, Satheesh Sertic, Andrew Liu, Zhihui (Amy) Liu, Zijin Darling, Gail E. Yeung, Jonathon Wong, Rebecca Chen, Eric X. Kalimuthu, Sangeetha Allen, Michael J. Suzuki, Chihiro Panov, Elan Ma, Lucy X. Bach, Yvonne Jang, Raymond W. Swallow, Carol J. Brar, Savtaj Elimova, Elena Veit-Haibach, Patrick Front Oncol Oncology OBJECTIVES: To identify combined clinical, radiomic, and delta-radiomic features in metastatic gastroesophageal adenocarcinomas (GEAs) that may predict survival outcomes. METHODS: A total of 166 patients with metastatic GEAs on palliative chemotherapy with baseline and treatment/follow-up (8–12 weeks) contrast-enhanced CT were retrospectively identified. Demographic and clinical data were collected. Three-dimensional whole-lesional radiomic analysis was performed on the treatment/follow-up scans. “Delta” radiomic features were calculated based on the change in radiomic parameters compared to the baseline. The univariable analysis (UVA) Cox proportional hazards model was used to select clinical variables predictive of overall survival (OS) and progression-free survival (PFS) (p-value <0.05). The radiomic and “delta” features were then assessed in a multivariable analysis (MVA) Cox model in combination with clinical features identified on UVA. Features with a p-value <0.01 in the MVA models were selected to assess their pairwise correlation. Only non-highly correlated features (Pearson’s correlation coefficient <0.7) were included in the final model. Leave-one-out cross-validation method was used, and the 1-year area under the receiver operating characteristic curve (AUC) was calculated for PFS and OS. RESULTS: Of the 166 patients (median age of 59.8 years), 114 (69%) were male, 139 (84%) were non-Asian, and 147 (89%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. The median PFS and OS on treatment were 3.6 months (95% CI 2.86, 4.63) and 9 months (95% CI 7.49, 11.04), respectively. On UVA, the number of chemotherapy cycles and number of lesions at the end of treatment were associated with both PFS and OS (p < 0.001). ECOG status was associated with OS (p = 0.0063), but not PFS (p = 0.054). Of the delta-radiomic features, delta conventional HUmin, delta gray-level zone length matrix (GLZLM) GLNU, and delta GLZLM LGZE were incorporated into the model for PFS, and delta shape compacity was incorporated in the model for OS. Of the treatment/follow-up radiomic features, shape compacity and neighborhood gray-level dependence matrix (NGLDM) contrast were used in both models. The combined 1-year AUC (Kaplan–Meier estimator) was 0.82 and 0.81 for PFS and OS, respectively. CONCLUSIONS: A combination of clinical, radiomics, and delta-radiomic features may predict PFS and OS in GEAs with reasonable accuracy. Frontiers Media S.A. 2023-08-14 /pmc/articles/PMC10461093/ /pubmed/37645426 http://dx.doi.org/10.3389/fonc.2023.892393 Text en Copyright © 2023 Krishna, Sertic, Liu, Liu, Darling, Yeung, Wong, Chen, Kalimuthu, Allen, Suzuki, Panov, Ma, Bach, Jang, Swallow, Brar, Elimova and Veit-Haibach https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Krishna, Satheesh
Sertic, Andrew
Liu, Zhihui (Amy)
Liu, Zijin
Darling, Gail E.
Yeung, Jonathon
Wong, Rebecca
Chen, Eric X.
Kalimuthu, Sangeetha
Allen, Michael J.
Suzuki, Chihiro
Panov, Elan
Ma, Lucy X.
Bach, Yvonne
Jang, Raymond W.
Swallow, Carol J.
Brar, Savtaj
Elimova, Elena
Veit-Haibach, Patrick
Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
title Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
title_full Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
title_fullStr Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
title_full_unstemmed Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
title_short Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
title_sort combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461093/
https://www.ncbi.nlm.nih.gov/pubmed/37645426
http://dx.doi.org/10.3389/fonc.2023.892393
work_keys_str_mv AT krishnasatheesh combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT serticandrew combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT liuzhihuiamy combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT liuzijin combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT darlinggaile combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT yeungjonathon combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT wongrebecca combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT chenericx combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT kalimuthusangeetha combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT allenmichaelj combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT suzukichihiro combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT panovelan combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT malucyx combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT bachyvonne combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT jangraymondw combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT swallowcarolj combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT brarsavtaj combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT elimovaelena combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma
AT veithaibachpatrick combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma